IP Library Granted Patent US 8,058,006
Granted Patent B2
US 8,058,006 · App. 12/301,602 · Granted Nov 15, 2011

Method for obtaining and initiating amplification of a target nucleic acid sequence

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,058,006
App. No.
12/301,602
Granted
Nov 15, 2011
Kind
B2
Abstract

The present invention relates to oligonucleotides useful for determining the presence of Mycobacterium tuberculosis complex organisms in a test sample. The oligonucleotides of the present invention may be incorporated into detection probes, helper probes, capture probes and amplification oligonucleotides, and used in various combinations thereof.

Claims (20)

1. A method for obtaining and initiating amplification of a target nucleic acid sequence from a mycobacterial organism present in a sample, the method comprising the steps of:

a) exposing a sample to a lytic composition for about 15 minutes to at least, or about, 60 minutes under conditions sufficient to kill and lyse said organism that include a temperature of about 60° C. to at least, or about, 95° C., thereby releasing a target nucleic acid into a lysate, the lytic composition comprising a detergent, an amplification oligonucleotide for amplifying a target nucleic acid sequence contained in the target nucleic acid, a solid support comprising a plurality of magnetically charged particles or beads, and a capture probe for immobilizing the target nucleic acid on the solid support;

b) forming a hybrid complex in the lysate, which hybrid complex comprises the capture probe, the target nucleic acid and the amplification oligonucleotide;

c) immobilizing the hybrid complex on the solid support and removing components of the lysate which are not part of the hybrid complex formed in step b); and

d) exposing the target nucleic acid to amplification conditions, such that the amplification oligonucleotide is enzymatically extended to form a complementary copy of the target nucleic acid sequence.

2. The method of claim 1 , wherein the temperature of step b) is lower than the temperature of step a).

3. The method of claim 1 , wherein the sample is exposed to the lytic composition for at least, or about, 15 minutes under conditions that include a temperature of at least, or about, 95° C.

4. The method of claim 1 , wherein the amplification oligonucleotide comprises a promoter sequence which is recognized by an RNA polymerase.

5. The method of claim 1 , wherein the detergent is a cationic detergent.

6. The method of claim 5 , wherein the detergent is lithium lauryl sulfate.

7. The method of claim 5 , wherein the detergent is present at a concentration of from about 0.1 to about 5% (v/v) in step a).

8. The method of claim 5 , wherein the detergent is present at a concentration of from about 0.1 to about 3% (v/v) in step a).

9. The method of claim 5 , wherein the detergent is present at a concentration of from about 0.1 to about 1.5% (v/v) in step a).

10. The method of claim 5 , wherein the detergent is present at a concentration of from about 0.1 to about 0.3% (v/v) in step a).

11. The method of claim 1 , wherein mechanical means are not used to lyse the organism.

12. The method of claim 1 , wherein sonication is not used to lyse the organism.

13. The method of claim 1 , wherein the salt concentration of steps a)-c) is from about 0.6 M to about 0.9 M.

14. The method of claim 1 , wherein the sample is a respiratory sample.

15. The method of claim 14 , wherein the respiratory sample is sputum.

16. The method of claim 1 , where the mycobacterial organism is a Mycobacterium tuberculosis complex organism.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →